Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.55 USD

86.55
3,439,683

-1.04 (-1.19%)

Updated Nov 15, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

Company News for Jul 28, 2022

Companies In The News Are: BSX, TMUS, WM, ROK.

Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 4.76% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stocks' Earnings Due on Jul 27: BSX, HOLX & ALGN

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how BSX, HOLX and ALGN fare this time.

PETQ vs. BSX: Which Stock Is the Better Value Option?

PETQ vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Boston Scientific (BSX) in Q2 Earnings?

Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.

The Zacks Analyst Blog Highlights Adobe, The Southern Company, Northrop Grumman, Boston Scientific, Marathon Petroleum and Archer-Daniels-Midland

Adobe, The Southern Company, Northrop Grumman, Boston Scientific, Marathon Petroleum and Archer-Daniels-Midland have been included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Adobe, Southern Company & Northrop Grumman

Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), The Southern Company (SO), and Northrop Grumman Corporation (NOC).

Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout

According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.

Here's Why You Should Retain Boston Scientific (BSX) for Now

Investors are optimistic about Boston Scientific's (BSX) strong organic sales and notable acquisitions.

Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails

Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.

Boston Scientific (BSX) Down 6.1% Since Last Earnings Report: Can It Rebound?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sheraz Mian headshot

Top Analyst Reports for Adobe, Danaher, Equinor & Others

Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Danaher Corporation (DHR), and Equinor ASA (EQNR).

Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Boston Scientific (BSX) Tops Q1 Earnings and Revenue Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Riya Anand headshot

Medical Device Stock Earnings Roster for Apr 27: BSX, HOLX & More

Medical device stocks' Q1 earnings will likely reflect rebound in base business. Let's see how Boston Scientific (BSX), Hologic (HOLX), Align Technology (ALGN) and Integra (IART) will fare in Q1.

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

Given an innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, Boston Scientific (BSX) is well-positioned to register strong first quarter of 2022 results.

Why Boston Scientific (BSX) Could Beat Earnings Estimates Again

Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Retain Boston Scientific (BSX) For Now

Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.

Boston Scientific (BSX) Hurt by Price and Volume Issues

The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.

Boston Scientific (BSX) Up 3.2% Since Last Earnings Report: Can It Continue?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Union Pacific & Freeport-McMoRan

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Union Pacific Corporation (UNP), and Freeport-McMoRan Inc. (FCX).

Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.